P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA

P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA

Bibliographic Details
Main Authors:	Danielle H. Oh, Xiao MA, Jackson He, Conor Kearney, Simon J. Hogg, Andrea Newbold, Peter Fraser, Ian G. Jennings, Daniella Brasacchio, Olivia Susanto, Chun Yew Fong, Mark A. Dawson, Emily Gruber, Lev Kats, Ricky W. Johnstone, Philip E. Thompson, Jake Shortt
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971744.43694.69

Similar Items

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
by: Vittoria Graziani, et al.
Published: (2023-01-01)

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
by: Delmore, Jake E., et al.
Published: (2014)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Fraser Aird, et al.
Published: (2017-01-01)

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Fraser Aird, et al.
Published: (2018-01-01)

Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)

Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
by: Bandopadhayay, Pratiti, et al.
Published: (2020)

Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012)

Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
by: Jennings, L, et al.
Published: (2018)

Inhibition of BET bromodomain targets genetically diverse glioblastoma.
by: Cheng, Z, et al.
Published: (2013)

Interactome rewiring following pharmacological targeting of BET bromodomains
by: Lambert, J-P, et al.
Published: (2018)

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
by: Cheng, Z, et al.
Published: (2013)

Chemical probes and inhibitors of bromodomains outside the BET family
by: Moustakim, M, et al.
Published: (2016)

Discovery of BET bromodomain inhibitors and their role in target validation
by: Mueller, S, et al.
Published: (2014)

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
by: Chaidos, A, et al.
Published: (2014)

Evaluation of linker length effects on a BET bromodomain probe
by: Traquete, R, et al.
Published: (2019)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
by: Kenneth K. W. To, et al.
Published: (2023-03-01)

BET bromodomain proteins regulate enhancer function during adipogenesis
by: Brown, Jonathan D., et al.
Published: (2018)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
by: Filippakopoulos, P, et al.
Published: (2012)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
by: Lori, L, et al.
Published: (2016)

Synthesis and biological investigation of (+)-JD1, an organometallic BET bromodomain inhibitor
by: Hassell-Hart, S, et al.
Published: (2019)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
by: Picaud, S, et al.
Published: (2013)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
by: Hay, D, et al.
Published: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
by: Picaud, S, et al.
Published: (2013)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
by: Filippakopoulos, P, et al.
Published: (2012)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
by: Noah R. Flynn, et al.
Published: (2021-06-01)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
by: Zhi-Qiang Wang, et al.
Published: (2023-11-01)

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
by: Shu, Shaokun, et al.
Published: (2017)

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
by: Bowen Wang, et al.
Published: (2015-11-01)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
by: Elisa Funck-Brentano, et al.
Published: (2021-01-01)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
by: Martin V. Nguyen, et al.
Published: (2020-02-01)

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
by: Picaud, S, et al.
Published: (2013)

BRD3 and BRD4 BET bromodomain proteins differentially regulate skeletal myogenesis
by: Roberts, T, et al.
Published: (2017)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
by: Noemi Martella, et al.
Published: (2023-03-01)

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
by: Shumei Song, et al.
Published: (2020-06-01)

Addition to article 1212-98
by: Richards, S, et al.
Published: (1998)

BET Bromodomain Degradation Disrupts Function but Not 3D Formation of RNA Pol2 Clusters
by: Diana H. Chin, et al.
Published: (2023-01-01)

Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1
by: Meropi Bagka, et al.
Published: (2023-07-01)

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
by: Mengjun Zhong, et al.
Published: (2022-08-01)